News
Agilent Authorizes $2 Billion Share Repurchase Program
Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. PST
Puma Biotechnology Releases Updated Corporate Presentation
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31
Dexcom Appoints Teri Lawver as Chief Commercial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
EQS-News: BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the
QIAGEN schließt Übernahme von Verogen ab und stärkt führende Position im Bereich Forensik mit NGS-Technologien
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute den Abschluss der Übernahme von Verogen bekannt gegeben – einem führenden Unternehmen im Bereich Next-Generation-Sequencing-Technologien
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it has requested, jointly with
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces it has received
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for
QIAGEN und Helix vereinbaren exklusive Partnerschaft, um Next-Generation-Sequencing-Begleitdiagnostika für Erbkrankheiten voranzubringen
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) hat heute eine exklusive strategische Partnerschaft mit dem in Kalifornien ansässigen, führenden Unternehmen der Populationsgenomik Helix bekannt
Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress
Waters Corporation (NYSE:WAT) announced awards and recognitions from multiple independent industry organizations throughout 2022, highlighting strength and momentum of the company’s product
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard